 Claudia Clavijo
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tandem Mass Spectrometry | 8 | 2020 | 577 | 1.080 |
Why?
| | Recurrent Laryngeal Nerve Injuries | 1 | 2024 | 16 | 0.850 |
Why?
| | Gynecologic Surgical Procedures | 1 | 2024 | 64 | 0.830 |
Why?
| | Analgesics, Opioid | 5 | 2024 | 1143 | 0.720 |
Why?
| | Electromyography | 1 | 2024 | 415 | 0.710 |
Why?
| | Pain Management | 1 | 2024 | 405 | 0.650 |
Why?
| | Substance Abuse Detection | 1 | 2021 | 106 | 0.600 |
Why?
| | Spine | 1 | 2021 | 182 | 0.590 |
Why?
| | Chromatography, High Pressure Liquid | 5 | 2013 | 598 | 0.570 |
Why?
| | Sirolimus | 4 | 2010 | 281 | 0.470 |
Why?
| | Chromatography, Liquid | 3 | 2020 | 454 | 0.390 |
Why?
| | Morphine | 2 | 2011 | 171 | 0.380 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 601 | 0.370 |
Why?
| | Intraoperative Neurophysiological Monitoring | 2 | 2024 | 32 | 0.360 |
Why?
| | Blood Volume | 1 | 2011 | 65 | 0.340 |
Why?
| | Morphine Derivatives | 1 | 2011 | 19 | 0.340 |
Why?
| | Therapeutic Equivalency | 1 | 2010 | 31 | 0.320 |
Why?
| | Fentanyl | 1 | 2011 | 127 | 0.310 |
Why?
| | Drugs, Generic | 1 | 2010 | 27 | 0.310 |
Why?
| | Biological Availability | 1 | 2010 | 142 | 0.310 |
Why?
| | Drug Approval | 1 | 2010 | 91 | 0.300 |
Why?
| | Immunosuppressive Agents | 2 | 2010 | 847 | 0.280 |
Why?
| | Naltrexone | 1 | 2008 | 118 | 0.250 |
Why?
| | Dried Blood Spot Testing | 2 | 2020 | 126 | 0.230 |
Why?
| | Analgesia, Patient-Controlled | 1 | 2024 | 16 | 0.220 |
Why?
| | False Negative Reactions | 1 | 2024 | 61 | 0.210 |
Why?
| | Monitoring, Intraoperative | 1 | 2024 | 64 | 0.210 |
Why?
| | Quality Control | 1 | 2024 | 163 | 0.210 |
Why?
| | Neck | 1 | 2024 | 108 | 0.200 |
Why?
| | Hysterectomy | 1 | 2024 | 138 | 0.200 |
Why?
| | Pain Measurement | 1 | 2024 | 555 | 0.180 |
Why?
| | Spinal Curvatures | 1 | 2020 | 7 | 0.160 |
Why?
| | Evoked Potentials, Motor | 1 | 2020 | 50 | 0.160 |
Why?
| | Anesthetics, Intravenous | 1 | 2020 | 69 | 0.160 |
Why?
| | Chagas Cardiomyopathy | 1 | 2020 | 27 | 0.150 |
Why?
| | Propofol | 1 | 2020 | 85 | 0.150 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2020 | 111 | 0.150 |
Why?
| | Drug-Eluting Stents | 2 | 2010 | 88 | 0.150 |
Why?
| | Anesthesia, General | 1 | 2020 | 118 | 0.150 |
Why?
| | Methadone | 1 | 2020 | 122 | 0.140 |
Why?
| | Humans | 17 | 2024 | 144957 | 0.120 |
Why?
| | Lidocaine | 2 | 2020 | 54 | 0.120 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 392 | 0.120 |
Why?
| | Polysomnography | 1 | 2017 | 235 | 0.120 |
Why?
| | Ondansetron | 1 | 2014 | 19 | 0.110 |
Why?
| | Pilot Projects | 1 | 2021 | 1890 | 0.110 |
Why?
| | Serotonin Antagonists | 1 | 2014 | 30 | 0.110 |
Why?
| | Middle Aged | 5 | 2024 | 35928 | 0.110 |
Why?
| | Sensitivity and Specificity | 3 | 2020 | 1990 | 0.110 |
Why?
| | Neonatal Abstinence Syndrome | 1 | 2014 | 27 | 0.100 |
Why?
| | Colorado | 1 | 2024 | 4564 | 0.100 |
Why?
| | Cohort Studies | 1 | 2024 | 5965 | 0.100 |
Why?
| | Hydroxyurea | 1 | 2013 | 34 | 0.100 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2013 | 34 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2013 | 3415 | 0.100 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2017 | 300 | 0.090 |
Why?
| | Cerebrospinal Fluid | 1 | 2013 | 88 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2024 | 8279 | 0.090 |
Why?
| | Prospective Studies | 2 | 2021 | 7997 | 0.090 |
Why?
| | Limit of Detection | 1 | 2011 | 97 | 0.080 |
Why?
| | Anesthetics, Local | 1 | 2011 | 100 | 0.080 |
Why?
| | Young Adult | 3 | 2024 | 14126 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 264 | 0.080 |
Why?
| | Giant Cells | 1 | 2010 | 21 | 0.080 |
Why?
| | Coronary Restenosis | 1 | 2010 | 22 | 0.080 |
Why?
| | Tunica Intima | 1 | 2010 | 79 | 0.080 |
Why?
| | Mycophenolic Acid | 1 | 2010 | 120 | 0.070 |
Why?
| | Cesarean Section | 1 | 2011 | 224 | 0.070 |
Why?
| | Female | 6 | 2024 | 78376 | 0.070 |
Why?
| | United States Food and Drug Administration | 1 | 2010 | 205 | 0.070 |
Why?
| | Tacrolimus | 1 | 2010 | 196 | 0.070 |
Why?
| | Retrospective Studies | 2 | 2024 | 17101 | 0.070 |
Why?
| | Dogs | 1 | 2008 | 438 | 0.060 |
Why?
| | Molecular Structure | 1 | 2008 | 501 | 0.060 |
Why?
| | Aged | 2 | 2024 | 25947 | 0.060 |
Why?
| | Narcotic Antagonists | 1 | 2008 | 206 | 0.060 |
Why?
| | Adult | 4 | 2024 | 40506 | 0.050 |
Why?
| | Adolescent | 1 | 2024 | 22453 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2017 | 2920 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2014 | 2032 | 0.050 |
Why?
| | Male | 4 | 2024 | 72406 | 0.040 |
Why?
| | Dexmedetomidine | 1 | 2020 | 44 | 0.040 |
Why?
| | Ketamine | 1 | 2020 | 133 | 0.040 |
Why?
| | Neurosurgical Procedures | 1 | 2020 | 202 | 0.030 |
Why?
| | Delphi Technique | 1 | 2020 | 331 | 0.030 |
Why?
| | Consensus | 1 | 2020 | 489 | 0.030 |
Why?
| | Snoring | 1 | 2017 | 18 | 0.030 |
Why?
| | Spinal Cord | 1 | 2020 | 382 | 0.030 |
Why?
| | Perioperative Period | 1 | 2017 | 71 | 0.030 |
Why?
| | Preoperative Period | 1 | 2017 | 149 | 0.030 |
Why?
| | Echocardiography | 1 | 2020 | 652 | 0.030 |
Why?
| | Oximetry | 1 | 2017 | 126 | 0.030 |
Why?
| | Postoperative Period | 1 | 2017 | 354 | 0.030 |
Why?
| | Drug Monitoring | 1 | 2020 | 395 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2020 | 699 | 0.030 |
Why?
| | Postoperative Care | 1 | 2017 | 288 | 0.030 |
Why?
| | Drug Administration Routes | 1 | 2014 | 44 | 0.030 |
Why?
| | Risk | 1 | 2017 | 911 | 0.030 |
Why?
| | Drug Stability | 1 | 2013 | 164 | 0.020 |
Why?
| | Inpatients | 1 | 2017 | 546 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2014 | 783 | 0.020 |
Why?
| | Cell Proliferation | 2 | 2010 | 2499 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1660 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1563 | 0.020 |
Why?
| | United States | 1 | 2010 | 15988 | 0.020 |
Why?
| | Oxygen | 1 | 2017 | 995 | 0.020 |
Why?
| | Anesthesia, Epidural | 1 | 2011 | 12 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1486 | 0.020 |
Why?
| | Length of Stay | 1 | 2017 | 1337 | 0.020 |
Why?
| | Postoperative Nausea and Vomiting | 1 | 2011 | 25 | 0.020 |
Why?
| | Child | 1 | 2011 | 22657 | 0.020 |
Why?
| | Anesthesia, Obstetrical | 1 | 2011 | 30 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2017 | 916 | 0.020 |
Why?
| | Linear Models | 1 | 2013 | 854 | 0.020 |
Why?
| | Endpoint Determination | 1 | 2011 | 83 | 0.020 |
Why?
| | Area Under Curve | 1 | 2011 | 331 | 0.020 |
Why?
| | Delayed-Action Preparations | 1 | 2011 | 183 | 0.020 |
Why?
| | Swine, Miniature | 1 | 2010 | 89 | 0.020 |
Why?
| | Half-Life | 1 | 2010 | 151 | 0.020 |
Why?
| | Pregnancy | 2 | 2014 | 7191 | 0.020 |
Why?
| | Drug Interactions | 1 | 2011 | 401 | 0.020 |
Why?
| | Granuloma | 1 | 2010 | 96 | 0.020 |
Why?
| | Animals | 2 | 2010 | 38109 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2010 | 334 | 0.020 |
Why?
| | Fibrin | 1 | 2010 | 91 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2017 | 1177 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2010 | 423 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 4275 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5872 | 0.020 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 266 | 0.020 |
Why?
| | Swine | 1 | 2010 | 833 | 0.020 |
Why?
| | Wound Healing | 1 | 2010 | 351 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2010 | 2029 | 0.010 |
Why?
| | Risk Factors | 1 | 2017 | 10792 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 6434 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 11695 | 0.010 |
Why?
| | Inflammation | 1 | 2010 | 2880 | 0.010 |
Why?
|
|
Clavijo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|